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Objectives: Lung injury is a serious complication of cardiopulmonary bypass in
infants with congenital heart disease and pulmonary hypertension. Cessation of
blood flow in the pulmonary arteries during cardiopulmonary bypass is known to
provoke lung dysfunction. We assessed the effect of continuous pulmonary perfu-
sion on circulating adhesion molecules and on lung function.
Methods: Fourteen infants with congenital heart disease and pulmonary hyperten-
sion were enrolled in the study. During total cardiopulmonary bypass, 8 patients
underwent continuous perfusion of the pulmonary arteries (perfusion group), and
the remaining 6 patients did not (control group). Plasma levels of circulating inter-
cellular adhesion molecule 1, soluble granule membrane protein 140, and sialyl
Lewisx and PaO2/fraction of inspired oxygen ratios were measured before com-
mencement and serially for 24 hours after termination of bypass.
Results: Plasma levels of circulating intercellular adhesion molecule 1 decreased
significantly at the termination of bypass in both groups but returned to prebypass
levels immediately in the control group, whereas in the perfusion group the values
remained significantly less than those before bypass. Plasma levels of soluble gran-
ule membrane protein 140 in the control group were significantly higher at 6 and 12
hours after bypass than levels before bypass, whereas in the perfusion group the val-
ues remained at the prebypass level throughout the postbypass period. Trends of
plasma levels of sialyl Lewisx were alike in both groups. PaO2/fraction of inspired
oxygen ratios in the control group decreased significantly from 6 hours after bypass,
whereas values in the perfusion group remained at the prebypass value throughout
the postbypass period.
Conclusions: This study suggests that in infants having congenital heart disease and
pulmonary hypertension, continuous pulmonary perfusion during total cardiopul-
monary bypass minimizes ischemic insult and neutrophil-endothelial interaction
mediated by adhesion molecules in the pulmonary microvessels.
Postoperative dysfunction of the lung remains a life-threateningcomplication of cardiopulmonary bypass (CPB), particularly ininfants with congenital heart disease and pulmonary hypertension.1An earlier study demonstrated that exposure of blood to the syn-thetic surface of the CPB circuit activated complements, therebyprovoking a systemic inflammatory response.2 Activated comple-
ments in turn played a crucial role in the activation and sequestration of neu-
trophils in the lung, causing subsequent damage, particularly to the endothelium.
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In the physiologic process of the inflammatory reaction,
expression and release of cytokines are also known to
play a crucial role in regulating the cell-to-cell interaction
mediated by adhesion molecules.3 In addition, the sys-
temic inflammatory response provoked by CPB has a par-
ticularly deleterious effect on the lung, with an additional
insult occurring as a result of ischemia of the lung. During
total CPB, the lung is perfused solely by the bronchial
arterial system, and therefore the lung is at risk for the
development of ischemic insult. Furthermore, accumula-
tion or extensive sequestration of neutrophils is known to
occur in the lung, commonly when the pulmonary circu-
lation is reestablished.4 Earlier reports demonstrated fur-
ther that reperfusion after an ischemic insult to the lung
aggravated structural and functional abnormalities of the
pulmonary endothelial cells, with an ensuing result of
progressive injury to the lung. In such an injurious
process, neutrophil-endothelial interaction mediated by
adhesion molecules is known to play a crucial role.5 This
evidence was partly exemplified by experimental studies
in which the lung injury was much less severe with lesser
deprivation of blood flow in the pulmonary arteries during
CPB or partial CPB than during total CPB.6,7
Cumulated knowledge referring to the mechanism of
lung injury during CPB led us to an assumption that restored
flow of blood in the pulmonary arteries during total CPB
would prevent ischemic insult, as well as reperfusion injury,
to the lung. We therefore performed continuous perfusion of
the pulmonary arteries during total CPB in infants having
congenital heart disease and pulmonary hypertension, with
a favorable outcome represented by the well-preserved ratio
of arterial oxygen tension to inspired oxygen fraction
(PaO2/FIO2 ratio), less duration of postoperative mechanical
ventilation, and less neutrophil sequestration in the lung.8 In
view of neutrophil-endothelial interaction, we conducted
this study to identify whether continuous perfusion of the
pulmonary arteries had any effect on plasma levels of circu-
lating adhesion molecules.
Methods
Patients
Fourteen consecutive infants with either ventricular septal defect
or atrioventricular septal defect and pulmonary hypertension
underwent definitive surgical repair between January 1997 and
June 1998 and were enrolled in the study. Pulmonary hypertension
was defined as a pulmonary/systemic arterial systolic pressure
ratio of greater than 0.5. Thirteen patients had a ventricular septal
defect and 1 patient had the complete form of atrioventricular sep-
tal defect. Ages of the patients at the definitive surgical repair
ranged from 2 to 11 months, with a mean of 6.2 ± 2.7 months.
Patients were allocated randomly to the perfusion (n = 8) and con-
trol (n = 6) groups. During total CPB, the perfusion group under-
went continuous perfusion of the pulmonary arteries, whereas the
control group did not. This study was approved by the Ethics
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Committee of Tokyo Metropolitan Children’s Hospital, and
informed consent was obtained from all parents of the patients.
Operative Techniques
CPB. The circuit of the CPB comprised a roller pump
(Stöckert Instrument GmbH, Munich, Germany) and membrane
oxygenator (Lilliput 1-D901, Lilliput 2-D902; DIDECO S.p.A,
Mirandola, Italy). The circuit was primed with lactated Ringer’s
solution, albumin, mannitol, and leukocyte-depleted packed red
blood cells. Depletion of the leukocyte was achieved with a
leukocyte removal filter (Sepacell; Asahi Medical Co, Ltd,
Tokyo, Japan). Anticoagulation was accomplished by means of
intravenous administration of heparin sulfate (300 IU/kg), which
was neutralized with protamine sulfate at the end of CPB. A
nonpulsatile flow of 150 mL · kg–1 · min–1 was maintained
throughout CPB. All patients were cooled to moderate hypother-
mia ranging from 30°C to 32°C. Cardiac arrest was accom-
plished by means of aortic crossclamping coupled with infusion
of high-potassium (20 mEq/L) blood cardioplegic solution (20
mL/kg) through the aortic root. The same solution was repeat-
edly infused in 60-minute intervals (10 mL/kg) during aortic
crossclamping and immediately before unclamping. Blood gas
management during CPB was directed toward maintenance of
pH at 7.35 to 7.40 and PaCO2 at 35 to 40 mm Hg. PaO2 was main-
tained higher than 200 mm Hg. Blood gas management was con-
ducted according to the principle of alpha-stat management, in
which temperature correction of the measured pH and PaCO2
was not performed. Hemofiltration of the perfusate with the
hemoconcentrator (PANFLO APF-01D; Asahi Medical Co, Ltd)
with or without supplemental transfusion of leukocyte-depleted
packed red blood cells was performed to keep the hematocrit
level greater than 25%. As was described in the previous report,8
the perfusion group underwent continuous perfusion of the oxy-
genated blood to the pulmonary arteries at a flow rate of 30 mL
· kg–1 · min–1 during total CPB. The perfusate was infused into
the pulmonary trunk through an 18-gauge pediatric cardioplegia
cannula (DLP, Inc, Grand Rapids, Mich) and was drained out
from the left atrium through a vent circuit to secure a bloodless
field. By contrast, the control group did not undergo the corre-
sponding perfusion to the pulmonary arteries, with flow of blood
to the pulmonary arteries being arrested during total CPB.
Anesthesia and postoperative management. Anesthetic man-
agement comprised weight-related doses of morphine sulfate (50-
100 µg · kg–1 · h–1) and incremental doses of pancuronium bromide
(0.2 mg/kg) as required for neuromuscular blockade. During total
CPB, mechanical ventilation was arrested in both groups at the
positive end-expiratory pressure of 5 cm H2O. Postoperatively, all
patients were kept sedated with continuous intravenous infusion of
morphine sulfate (30-80 µg · kg–1 · h–1). Continuous infusion of
midazolam (0.05-0.1 µg · kg–1 · h–1) and repeated doses of pan-
curonium bromide (0.2 mg/kg) were added as needed. All patients’
lungs were ventilated mechanically for at least 24 hours after ter-
mination of CPB with the pressure-limited and time-cycled venti-
lator. The tidal volume was maintained at 8 to 10 mL/kg, and pos-
itive end-expiratory pressure was maintained at 5 cm H2O. FIO2
and ventilation rates were adjusted to keep PaO2 between 100 and
150 mm Hg and PaCO2 between 30 and 35 mm Hg. The airway was
kept clean by means of routine tracheal suctioning.
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Data Acquisition
Blood samples were taken from the peripheral systemic artery after
induction of anesthesia (prebypass value), at the termination of
CPB, and at 6, 12, and 24 hours after termination of CPB. Blood
samples were transferred to tubes containing ethylenediaminete-
traacetic acid, which were immediately cooled on ice, centrifuged
at 4°C (3000 rpm for 10 minutes), and stored at –20°C for later
measurements. Circulating intercellular adhesion molecule 1
(cICAM-1) was measured by means of a commercial standardized
enzyme-linked immunosorbent assay (Bender Medsystems,
Vienna, Austria). Soluble granule membrane protein 140
(sGMP140) was measured by means of a commercial standardized
enzyme-linked immunosorbent assay (Takara Shuzo, Tokyo,
Japan). Levels of sialyl Lewisx (sLex) was measured by a com-
mercial standardized immunoradiometric assay (Otsuka
Pharmaceuticals, Tokyo, Japan). Plasma levels were not standard-
ized by the hematocrit value.
Lung Function
Arterial blood gas analysis was performed concurrent with the
above measurements and also at 3 hours after termination of CPB
(Blood Gas System 288; Ciba Corning, Medfield, Mass). The
PaO2/FIO2 ratio was used as a parameter of lung function.
Statistical Analysis
Data were expressed as means ± SD. An unpaired t test was used
to determine differences between the groups. One-way repeated-
measures analysis of variance followed by the multiple compari-
son method was used to detect differences among the sampling
points within each group. Two-way repeated-measures analysis of
variance was used to determine differences between the groups
over time of the study.
Results
There were no significant differences between groups in
age, body weight, duration of CPB, duration of aortic cross-
clamping, preoperative pulmonary/systemic arterial systolic
pressure ratio, pulmonary/systemic flow ratio, and pul-
monary/systemic vascular resistance ratio (Table 1). No
postoperative deaths occurred in either of the groups. There
was no significant difference in the volume of blood loss
(perfusion group vs control group: 41.4 ± 26.6 vs 67.8 ±
77.9 mL, P = .4048) or the volume of transfused homolo-
gous blood (perfusion group vs control group: 39.7 ± 20.3
vs 45 ± 22.4 mL, P = .6634) during the period of this study.
Renal function, represented by serum levels of creatinine
and blood urea nitrogen, and the total volume of inotropic
agents were not significantly different between groups. In
addition, the ratio of pulmonary/systemic arterial systolic
pressure at the termination of CPB revealed no significant
difference between groups (perfusion group vs control
group: 0.35 ± 0.10 vs 0.26 ± 0.08, P = .1136).
Plasma Levels of Measured Variables
cICAM-1. Plasma levels of cICAM-1 in both groups
were similar before CPB (perfusion group: 332 ± 90.9
ng/mL; control group: 353.7 ± 97.1 ng/mL; P = .673), and
those in both groups decreased significantly at the moment
of its termination (perfusion group: 204.6 ± 37.9 ng/mL,
P < .0001; control group: 156.2 ± 95.5 ng/mL, P = .0075)
compared with prebypass levels (Figure 1). Plasma levels in
the control group returned to prebypass levels by 6 hours
Figure 1. Perioperative trends of plasma levels of cICAM-1 in the
perfusion (n = 8) and control (n = 6) groups. P values represent
results compared with prebypass values within each group.
Figure 2. Perioperative trends of plasma levels of sGMP140 in the
perfusion (n = 8) and control (n = 6) groups. P values represent
results compared with prebypass values within each group.
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after termination of CPB, whereas those of the perfusion
group remained significantly lower than the prebypass lev-
els throughout the postbypass period (6 hours: 267 ± 49.5
ng/mL, P = .0024; 12 hours: 243.8 ± 39.8 ng/mL, P < .0001;
24 hours: 260.1 ± 47.3 ng/mL, P = .0010). Although the
postbypass values at each time point were not significantly
different between groups, the values later than 6 hours after
termination of CPB tended to be lower in the perfusion
group than in the control group, and the trend revealed sig-
nificant differences between groups by means of 2-way
repeated-measures analysis of variance (P = .0386).
sGMP140. Prebypass values of sGMP140 were similar
in both groups (perfusion group: 177.2 ± 98.2 ng/mL; con-
trol group: 177.9 ± 98.3 ng/mL; P = .6519). Plasma levels
in the control group increased stepwise during the first 12
hours after the termination of CPB and remained at a high
level by 24 hours after CPB (Figure 2). By contrast, in the
perfusion group the value increased slightly at the termina-
tion of and 6 hours after the termination of CPB and then
remained at a low level at the ensuing time points. When
compared with the prebypass value within each group, the
postbypass values of the control group were significantly
higher at 6 hours (306.1 ± 215.8 ng/mL; P = .0425) and 12
hours (303.6 ± 223.3 ng/mL; P = .0462) after termination of
CPB, whereas those of the perfusion group did not show
significant difference throughout the postbypass period.
Although postbypass values at each time point were not sig-
nificantly different between groups, they tended to be lower
in the perfusion group compared with those in the control
group, with a trend toward significant difference between
groups, as determined by using 2-way repeated-measures
analysis of variance (P = .0458).
sLex.Prebypass values of sLeX were almost similar in
both groups (perfusion group: 35.6 ± 9.2 U/mL; control
group: 36.5 ± 5.1 U/mL; P = .627). The values of the con-
trol group decreased significantly at the termination of and
6 hours after the termination of CPB (termination of CPB:
30.2 ± 7.4 U/mL, P = .0291; 6 hours: 29.3 ± 4.9 U/mL, P =
.0155) and then returned to the prebypass level by 24 hours
after termination of CPB (Figure 3). By contrast, values of
the perfusion group remained significantly lower than the
prebypass value up to 12 hours after termination of the CPB
(termination of CPB: 27.1 ± 7.1 U/mL, P = .009; 6 hours:
24.9 ± 7.3 U/mL, P = .0009; 12 hours: 28.6 ± 6.4 U/mL, P
= .0357) and then returned to the prebypass value. Although
the postbypass values at each point were not significantly
different between groups, they tended to be lower in the per-
fusion group than in the control group.
Lung Function
Prebypass values of lung function were similar in both
groups (perfusion group: 388.7 ± 98.1; control group: 390.5
± 96.2). In the control group PaO2/FIO2 ratio decreased sig-
nificantly at 6 hours (269.6 ± 144.5; P = .0109), 12 hours
(259.5 ± 119.8; P = .0065), and 24 hours (290.5 ± 127.1; 
P = .0310) after termination of CPB (Figure 4). By contrast,
Figure 3. Perioperative trends of plasma levels of sLeX in the per-
fusion (n = 8) and control (n = 6) groups. P values represent results
compared with prebypass values within each group.
Figure 4. Postoperative trends of PaO2/FIO2 ratios in the perfusion
(n = 8) and control (n = 6) groups. P values represent results com-
pared with prebypass values within each group.
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in the perfusion group the values remained at the prebypass
level during the first 6 hours after termination of CPB and
then decreased at 12 and 24 hours after termination of CPB,
although not significantly. Duration of the mechanical sup-
port of ventilation tended to be less in the perfusion group
compared with that in the control group (perfusion group vs
control group: 34.5 ± 15.6 vs 65.8 ± 42.3 hours; P = .1896),
although the differences could be due to chance. Two
patients in the control group required nitric oxide inhalation
therapy for the management of episodic elevation of the pul-
monary arterial pressure. The treatment was commenced on
postoperative days 2 and 3, respectively, and was terminat-
ed within 3 days.
Discussion
In addition to the widely accepted concept that exposure of
blood to CPB is in itself the cause of lung injury, an increas-
ing number of studies have endorsed the view that cessation of
flow of blood in the pulmonary arteries during total CPB
aggravated the lung injury. Indeed, experimental studies clari-
fied the fact that lung injury was much less severe with lesser
deprivation of blood flow in the pulmonary arteries during
CPB or partial CPB than during total CPB.6,7 This could be
ascribed to the hemodynamic features during the convention-
al total CPB when the lung was perfused solely by the
bronchial arterial system, with the lung being exposed at the
risk of ischemic insult. On the basis of this evidence, we rea-
soned that restored flow of blood in the pulmonary arteries
during total CPB would offset the ischemic insult, as well as
the reperfusion injury, to the lung. Our previous study demon-
strated that the pulmonary perfusion technique favorably
affected the postoperative lung function, as was exemplified
by well-preserved PaO2/FIO2 ratios during the postbypass peri-
od coupled with less duration of postoperative support for ven-
tilation.8 This view was consistent with that of a recent exper-
imental work, in which the authors demonstrated that
additional low-flow perfusion of the lung during total CPB
demonstrated better preservation of tissue adenosine triphos-
phate stores and PaO2 in the neonatal piglet model.9
Meanwhile, recent advances of molecular biology have
expanded our view of the intricate mechanism of lung injury
and demonstrated that adhesion molecules, which regulated
interactions of the activated cell, were one of the initiating
factors of the pathophysiologic response of the inflammato-
ry reaction.10,11 Horgan and associates12 endorsed this con-
cept by claiming that in the setting of postischemic reperfu-
sion of the lung, upregulation of adhesion molecules on the
endothelial cell surface enhanced neutrophil-endothelial cell
adhesion and neutrophil sequestration, thereby producing
endothelial dysfunction and neutrophil-led tissue damage.
The adhesion molecule family of selectins, such as GMP-
140, mediated the initial rolling phase of neutrophil attach-
ment to endothelium binding to sLeX, which was found on
the neutrophil surface as a ligand. Subsequently, interaction
between the adhesion molecule families of integrins and
immunoglobulins, such as leukocyte function–associated
antigen, membrane attack complex-1, and ICAM-1, facilitat-
ed firm binding of neutrophils to the activated endotheli-
um.10 Additionally, soluble isoforms of adhesion molecules
were found to modulate the inflammatory process in many
different ways: by acting as a chemotoxin, by blocking neu-
trophil activation, or by competing with a membrane-bound
form of cell-to-cell adhesion.13
In view of the intrinsic role of the adhesion molecules,
the present study provided us with evidence that the contin-
uous perfusion of the pulmonary arteries suppressed eleva-
tion of plasma levels of cICAM-1 and sGMP140 during the
postbypass period. Recent investigators demonstrated ele-
vated plasma levels of cICAM-1 in patients with systemic
inflammatory response and organ dysfunction. Another
report supported this concept with pertinent evidence that
plasma levels of cICAM-1 were of prognostic value in
patients with organ failure.14 Recently, Rothlein and col-
leagues15 reported elevated plasma levels of cICAM-1 in the
setting of activated adhesion between membrane-bound
ICAM-1 and neutrophils and then presented a deductive
theory that cICAM-1 competed with membrane-bound
ICAM-1 for leukocyte adhesion to endothelium, thereby
TABLE 1. Characteristics of patients in perfused and control groups
Characteristic Perfusion group (n = 8) Control group (n = 6) P value
Age (mo) 5.9 ± 2.8 6.6 ± 2.7 .637
Body weight (kg) 4.2 ± 0.8 5.1 ± 1.0 .087
Pp/Ps 0.81 ± 0.21 0.76 ± 0.07 .646
Qp/Qs 3.18 ± 0.94 4.41 ± 1.9 .139
Rp/Rs 0.17 ± 0.05 0.16 ± 0.03 .901
Duration of CPB (min) 134.9 ± 35.5 134.2 ± 19.1 .966
Duration of AoX (min) 52.1 ± 22.9 51.2 ± 12.8 .929
AoX, Aortic crossclamp; CPB, cardiopulmonary bypass; Pp/Ps, pulmonary/systemic arterial systolic pressure ratio; Qp/Qs, pulmonary/systemic flow ratio;
Rp/Rs, pulmonary/systemic vascular resistance ratio.
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preventing neutrophil-induced tissue damage. In fact, inas-
much as the plasma level of cICAM-1 shows positive corre-
lation with the risk of organ dysfunction mediated by neu-
trophils, it is conceivable that the high plasma level is in
itself an important predictor of immune activation.
Regarding the effect of CPB on the plasma levels of
cICAM-1, the results of our study coincided with those of
another study arguing that in conventional CPB without per-
fusion of the pulmonary arteries, plasma levels of cICAM-1
decreased significantly during CPB and returned to baseline
value within a day after termination of CPB.16 Initial
descent of cICAM-1 could be attributed to its binding with
neutrophils activated by the systemic inflammatory
response to CPB. By contrast, ensuing low levels of
cICAM-1 throughout the postbypass period in the perfusion
group could be explained by the reasoning that the continu-
ous perfusion of the pulmonary arteries suppressed neu-
trophil-endothelial interaction in the pulmonary microves-
sels and release of cICAM-1, with a subsequent result of
well-preserved PaO2/FIO2 levels throughout the postbypass
period.
Sakamaki and associates17 demonstrated elevated plasma
levels of sGMP140 in patients with neutrophil-mediated
lung injury. The soluble form of GMP140 has been shown
to prevent CD18-dependent neutrophil adhesion to endothe-
lial cells in vitro, with elevated sGMP140 levels reflecting a
physiologic response in which excessive adhesion of neu-
trophils to endothelial cells has been downregulated.
Therefore, high plasma levels of sGMP140 are considered
to be another isolated predictor of lung injury mediated by
neutrophils. Regarding the effect of CPB without perfusion
of the pulmonary arteries on plasma levels of sGMP140, our
result was in agreement with that of another study.19 Initial
increase of sGMP140 in both groups reflected systemic
inflammatory response derived from CPB. High plasma lev-
els throughout the postbypass period in the control group
were consistent with low values of PaO2/FIO2. In the perfu-
sion group low levels of sGMP140 throughout the postby-
pass period reflected less activation of neutrophil-endothe-
lial interaction in the pulmonary microvessels, with
concurrent results of well-preserved PaO2/FIO2 ratios.
sLeX is the oligosaccharide ligand for selectins like
GMP140 and is expressed on the neutrophil surface, which
is rapidly shed after initial binding between neutrophils and
endothelium. Therefore, plasma levels of sLeX may increase
during the initial adhesion process between neutrophils and
endothelium. A recent study has demonstrated further that
infusion of a synthetic sLeX analog attenuated neutrophil-
dependent lung injury by binding to selectins.20 Although
there was no report describing the effect of CPB on the plas-
ma levels of sLeX, early descent of sLeX during the postby-
pass period implied that binding on the activated endotheli-
um selectins occurred. By contrast, subsequent lower levels
of sLeX in the perfusion group implied that the continuous
perfusion of the pulmonary arteries during total CPB favor-
ably affected the inflammatory process, suppressing neu-
trophil-endothelial interaction and release of sLeX in the
pulmonary microvessels.
In the various models of ischemia-reperfusion injury,
neutrophil recruitment was an indispensable event for the
full development of injury to organs. In our previous study,
we found that neutrophil sequestration in the lung was less
severe in the perfusion group.8 Moreover, our present results
suggested that continuous perfusion of the pulmonary arter-
ies during total CPB minimized ischemic insult and inhibit-
ed neutrophil sequestration by minimizing the neutrophil-
endothelial interaction mediated by adhesion molecules in
the pulmonary microvessels, with the evidence of sup-
pressed elevation of plasma levels of circulating adhesion
molecules and well-preserved values of PaO2/FIO2. A new
promising area of specific inhibition of inflammatory medi-
ators involves the use of a blocking monoclonal antibody.21
Although such an antibody is specifically effective in miti-
gating the inflammatory response, there remains some con-
cern as to whether exposure of patients to foreign proteins is
harmless. Moreover, the cause of lung injury derived from
CPB can be multifactorial. In this context, the continuous
pulmonary perfusion technique is a promising adjunctive
method that preserves lung function with a physiologic
mean during CPB. However, the clinical significance of sol-
uble adhesion molecules in plasma is still not fully under-
stood. Because no experimental work has been done related
to the endothelial expression of adhesion molecules during
total CPB coupled with or without pulmonary perfusion
technique, further investigative work may be required to
determine the precise effect of the continuous pulmonary
perfusion technique on the lung.
In conclusion, results of this study demonstrated that
ischemia and reperfusion of the lung during CPB were the
major factors contributing to lung injury in infants with con-
genital heart disease and pulmonary hypertension. Our
results suggest that continuous perfusion of the pulmonary
arteries during total CPB is a promising adjunctive method
to minimize the ischemic insult to the lung, as well as neu-
trophil-endothelial interaction mediated by adhesion mole-
cules in the pulmonary microvessels.
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